

# Sebastian Schwind

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/736692/publications.pdf>

Version: 2024-02-01

37  
papers

357  
citations

933447

10  
h-index

839539

18  
g-index

37  
all docs

37  
docs citations

37  
times ranked

691  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical value of the measurable residual disease status within the <scp>ELN2017</scp> risk groups in <scp>AML</scp> patients undergoing allogeneic stem cell transplantation. American Journal of Hematology, 2021, 96, E237-E239.	4.1	3
2	Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cellsâ€”Report on Two Cases. Frontiers in Oncology, 2021, 11, 737645.	2.8	4
3	Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Cancers, 2021, 13, 5679.	3.7	0
4	Case Report: Large Granular Lymphocyte Leukemia (LGLL)â€”A Case Series of Challenging Presentations. Frontiers in Oncology, 2021, 11, 775313.	2.8	3
5	Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML. Annals of Hematology, 2020, 99, 2417-2427.	1.8	1
6	Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation. Blood Advances, 2020, 4, 3864-3874.	5.2	36
7	High expression of the stem cell marker <i>GPR56</i> at diagnosis identifies acute myeloid leukemia patients at higher relapse risk after allogeneic stem cell transplantation in context with the CD34+/CD38- population. Haematologica, 2020, 105, e507.	3.5	12
8	Outcomes of Older Patients with <i>NPM1</i> Mutated and <i>FLT3</i>â€”TD Negative Acute Myeloid Leukemia Receiving Allogeneic Transplantation. HemaSphere, 2020, 4, e326.	2.7	6
9	Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy. Current Treatment Options in Oncology, 2020, 21, 8.	3.0	7
10	Comparison of nonâ€”myeloablative and reducedâ€”intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes. American Journal of Hematology, 2019, 94, 1344-1352.	4.1	7
11	Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia. Cancers, 2019, 11, 1625.	3.7	19
12	Pretreatment CD34+/CD38â€” Cell Burden as Prognostic Factor in Myelodysplastic Syndrome Patients Receiving Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1560-1566.	2.0	5
13	Prognostic Impact of Blood <i>MN1</i> Copy Numbers Before Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia. HemaSphere, 2019, 3, e167.	2.7	20
14	Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation. Bone Marrow Transplantation, 2019, 54, 1189-1197.	2.4	34
15	Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA. Leukemia, 2019, 33, 771-775.	7.2	15
16	Prognostic relevance of DNMT3A R882 mutations in AML patients undergoing non-myeloablative conditioning hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 640-643.	2.4	0
17	Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients. Annals of Hematology, 2018, 97, 1757-1765.	1.8	57
18	MicroRNA-143 targets ERK5 in granulopoiesis and predicts outcome of patients with acute myeloid leukemia. Cell Death and Disease, 2018, 9, 814.	6.3	23

#	ARTICLE	IF	CITATIONS
19	Phase II Study of Stimulation of Healthy Sibling Donors with Single-Shot Pegfilgrastim - Update (EUDRACT Nr: 2005-004971-39). <i>Blood</i> , 2018, 132, 2064-2064.	1.4	0
20	Prognostic impact of the CD34+/CD38 <sup>hi</sup> cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2017, 92, 388-396.	4.1	25
21	Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077). <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 2545-2553.	2.5	10
22	Disruption of the C/EBP $\beta$ -miR-182 balance impairs granulocytic differentiation. <i>Nature Communications</i> , 2017, 8, 46.	12.8	38
23	High BAALC copy numbers in peripheral blood prior to allogeneic transplantation predict early relapse in acute myeloid leukemia patients. <i>Oncotarget</i> , 2017, 8, 87944-87954.	1.8	19
24	Unsupervised hierarchical clustering of surface antigen expression to identify normal karyotype AML patients with distinct disease characteristics and poor outcome.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7042-7042.	1.6	0
25	High Blood BAALC Copy Numbers Determined By Digital Droplet PCR at Timepoint of Allogeneic Transplantation in Complete Remission Predicts Relapse in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 517-517.	1.4	0
26	Absolute Quantification of Pre-microRNA-155 Copy Numbers By Digital Droplet PCR Identifies Acute Myeloid Leukemia (AML) Patients with Adverse Outcome. <i>Blood</i> , 2016, 128, 1698-1698.	1.4	0
27	Biological Associations and Clinical Impact of Differential Expression of the Pre-Mir-29a/b-1 and Pre-Mir-29b-2/C Clusters in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 5110-5110.	1.4	0
28	High Expression of ZBTB7A at Diagnosis Associated with Inferior Outcome in Acute Myeloid Leukemia Patients Receiving Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 5092-5092.	1.4	0
29	Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 2013-2022.	2.5	11
30	Assessment of NPM1 Type a Mutation Burden By Digital Droplet PCR As a Marker of Minimal Residual Disease in Acute Myeloid Leukemia Patients Undergoing Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 4398-4398.	1.4	0
31	Inclusion of Plerixafor Increases the Efficacy of Stem Cell Harvesting in Poorly Mobilizing Patients with Multiple Myeloma and Lymphoma. <i>Blood</i> , 2015, 126, 5439-5439.	1.4	0
32	Prognostic Impact of Aberrant RUNX1 Expression in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 3829-3829.	1.4	0
33	Unsupervised Cluster Analysis of Antigen Expression Patterns Identifies Subgroups with Distinct Biological and Clinical Features in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 2573-2573.	1.4	0
34	High Expression of the Hedgehog Transcription Factor GLI1 Is Associated with Improved Outcomes in Patients with Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Non-Myeloablative Conditioning. <i>Blood</i> , 2015, 126, 2032-2032.	1.4	0
35	High Pri-Mir-181a-1 and Pri-Mir-181a-2 Expression Associates with Improved Outcomes in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning. <i>Blood</i> , 2014, 124, 732-732.	1.4	0
36	Prognostic Significance Of EVI1 expression In Acute Myeloid Leukemia Patients With Intermediate and Adverse Cytogenetic Risk Undergoing Allogeneic Hematopoietic Cell Transplantation With Reduced-Intensity Conditioning. <i>Blood</i> , 2013, 122, 3383-3383.	1.4	1

#	ARTICLE	IF	CITATIONS
37	5-Azacitidine Induces Hematologic Responses in a High Proportion of Patients with Acute Myeloid Leukaemia Refractory to or Not Eligible for Intensive Chemotherapy.. Blood, 2006, 108, 1953-1953.	1.4	1